CLINICAL TRIALS PROFILE FOR PRECEDEX

505(b)(2) Clinical Trials for PRECEDEX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Baylor College of Medicine	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Boston Children's Hospital	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Boston Children’s Hospital	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Children's Hospital of Philadelphia	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Erasmus Medical Center	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

All Clinical Trials for PRECEDEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00205712 ↗	Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids	Completed	National Alliance for Research on Schizophrenia and Depression	Phase 4	2003-02-01	Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available agents. However, emergence reactions are an important adverse effect of ketamine, characterized by transient changes in cognitive function, dissociation and mild schizophrenia-like symptoms. These cognitive and behavioral effects are dose-dependently induced by ketamine and other antagonists of the N-methyl-D-aspartate (NMDA) glutamate receptor. NMDA receptor hypofunction can disinhibit excitatory (cholinergic/glutamatergic) projections in key areas of the brain, and this has been proposed to explain key features of schizophrenia. Several treatments that block excessive excitatory transmitter release have also been shown to prevent cognitive and behavioral effects of ketamine-induced NMDA receptor hypofunction in humans. Alpha-2 adrenergic agonists, which can presynaptically inhibit acetylcholine release, can prevent mild ketamine-induced behavioral and cognitive symptoms in healthy human adults. However, this prevention strategy has not been evaluated in children. Children currently receive clinically-indicated treatment with the NMDA antagonist, ketamine, and this age group is an important target for pharmacological strategies aimed at the prevention of schizophrenia. This application proposes a double-blind, placebo-controlled, randomized trial to test the safety and effectiveness of dexmedetomidine, an FDA approved alpha-2 adrenergic agonist, in preventing ketamine-induced mental symptoms in children. Planned primary analyses will evaluate effects of the hypothesized prevention treatment on clinical and cognitive variables using analysis of variance (ANOVA). The proposed experiments are relevant to future prevention trials for individuals at risk for schizophrenia, and to preventing adverse effects of NMDA antagonist anesthetic agents (ketamine, nitrous oxide).
NCT00205712 ↗	Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids	Completed	Washington University School of Medicine	Phase 4	2003-02-01	Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available agents. However, emergence reactions are an important adverse effect of ketamine, characterized by transient changes in cognitive function, dissociation and mild schizophrenia-like symptoms. These cognitive and behavioral effects are dose-dependently induced by ketamine and other antagonists of the N-methyl-D-aspartate (NMDA) glutamate receptor. NMDA receptor hypofunction can disinhibit excitatory (cholinergic/glutamatergic) projections in key areas of the brain, and this has been proposed to explain key features of schizophrenia. Several treatments that block excessive excitatory transmitter release have also been shown to prevent cognitive and behavioral effects of ketamine-induced NMDA receptor hypofunction in humans. Alpha-2 adrenergic agonists, which can presynaptically inhibit acetylcholine release, can prevent mild ketamine-induced behavioral and cognitive symptoms in healthy human adults. However, this prevention strategy has not been evaluated in children. Children currently receive clinically-indicated treatment with the NMDA antagonist, ketamine, and this age group is an important target for pharmacological strategies aimed at the prevention of schizophrenia. This application proposes a double-blind, placebo-controlled, randomized trial to test the safety and effectiveness of dexmedetomidine, an FDA approved alpha-2 adrenergic agonist, in preventing ketamine-induced mental symptoms in children. Planned primary analyses will evaluate effects of the hypothesized prevention treatment on clinical and cognitive variables using analysis of variance (ANOVA). The proposed experiments are relevant to future prevention trials for individuals at risk for schizophrenia, and to preventing adverse effects of NMDA antagonist anesthetic agents (ketamine, nitrous oxide).
NCT00351299 ↗	Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium	Completed	Brigham and Women's Hospital	Phase 2	2006-01-01	The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium
NCT00363935 ↗	Bariatric Dose-ranging Study With Dexmedetomidine	Withdrawn	University of Texas Southwestern Medical Center	Phase 4	2007-01-01	After obtaining informed consent,80 morbidly obese ASA II-III patients undergoing laparoscopic bariatric surgery procedures would be randomly assigned to one of four study groups at UTSWMC at Dallas.Hemodynamic paarameters, recovery times, postoperative pain scores, the need for rescue analgesics and side effects will be recorded.The purpose of this study is to determine the optimal linfusion rate of dexmedetomidine for maintaining cardiovscular stability during general anesthesia.
NCT00390871 ↗	Acute Neurological ICU Sedation Trial (ANIST)	Completed	Daniel Hanley	Phase 2	2005-05-01	Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.

Clinical Trial Conditions for PRECEDEX

Condition Name

Condition Name for PRECEDEX
Intervention	Trials
Anesthesia	26
Pain	16
Sedation	15
Delirium	14

Condition MeSH

Condition MeSH for PRECEDEX
Intervention	Trials
Delirium	27
Emergence Delirium	18
Pain, Postoperative	18
Psychomotor Agitation	17

Clinical Trial Locations for PRECEDEX

Trials by Country

Trials by Country for PRECEDEX
Location	Trials
United States	140
Egypt	70
Korea, Republic of	28
Canada	24
Turkey	16

Trials by US State

Trials by US State for PRECEDEX
Location	Trials
Massachusetts	21
New York	14
Ohio	13
Pennsylvania	12
Texas	9

Clinical Trial Progress for PRECEDEX

Clinical Trial Phase

Clinical Trial Phase for PRECEDEX
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	2

Clinical Trial Status

Clinical Trial Status for PRECEDEX
Clinical Trial Phase	Trials
Completed	169
Recruiting	44
Unknown status	30

Clinical Trial Sponsors for PRECEDEX

Sponsor Name

Sponsor Name for PRECEDEX
Sponsor	Trials
Assiut University	23
Hospira, Inc.	17
Hospira, now a wholly owned subsidiary of Pfizer	17

Sponsor Type

Sponsor Type for PRECEDEX
Sponsor	Trials
Other	409
Industry	39
NIH	7

Precedex (dexmedetomidine) Clinical Trials Update, Market Analysis, and Exclusivity-Based Launch Projection

Last updated: July 30, 2026

Executive summary

• Therapy: Precedex is the branded formulation of dexmedetomidine for sedation in monitored anesthesia care and ICU adult patients requiring sedation.
• Trial activity: Public trial activity exists across sedation, perioperative, and ICU workflow endpoints, but the core IP and FDA pathway focus remains small-molecule exclusivity and product-specific formulation/labeling protections, not a rapidly expanding brand-new clinical program.
• Near- to mid-term competition: Expect pricing pressure from generic dexmedetomidine concentrates/solutions where FDA approvals and supply chains support it; branded share retention depends on hospital formulary positioning, clinician preference, and contract terms rather than new clinical differentiation.
• Exclusivity risk: For a mature small molecule, generic entry probability is high once product-specific exclusivities and any relevant patents on formulation, concentration, or method-of-use expire or are cleared through settlement/litigation.

What is Precedex (dexmedetomidine) and what FDA approvals define its current market?

Precedex is dexmedetomidine hydrochloride indicated for:

• Monitored anesthesia care (MAC) in adults to produce sedation.
• ICU sedation in adult patients requiring sedation.

Key commercial implication: These indications map to high-volume settings (OR and ICU) with purchasing concentrated in large hospital systems, where conversion to generic is typically driven by contract leverage and pharmacoeconomic positioning.

What dosage forms and strengths govern hospital use?

Precedex is supplied as an injectable solution (concentrate) used for ICU infusions and perioperative sedation regimens. Market access tends to be concentrated on:

• Standard infusion workflows (ICU)
• Procedural sedation protocols (OR/MAC)

What clinical trials for dexmedetomidine update the evidence base for Precedex?

Dexmedetomidine has a mature clinical footprint across:

• ICU sedation strategies
• Procedural and perioperative sedation
• Delirium, agitation, withdrawal, and extubation-related outcomes
• Comparative trials versus propofol and benzodiazepines

Trial update pattern for a mature branded product: New trials typically do not restart exclusivity for a known small molecule. They more often support:

• label expansion in some jurisdictions
• guideline inclusion and formulary confidence
• protocol standardization that increases uptake even after generic substitution

Which trial endpoints most frequently drive adoption?

In practice, sedation adoption depends on endpoints such as:

• time to sedation targets
• duration of ventilation and extubation endpoints
• delirium scoring and agitation control
• safety including bradycardia/hypotension rates
• hemodynamic stability vs comparators

Are there ongoing Phase 3 or registration-defining trials for Precedex?

For a marketed small-molecule sedation product, registration-defining trials for the brand are less common than:

• investigator-initiated comparative studies
• pragmatic ICU trials
• pathway-specific studies in perioperative care

Business takeaway: Treat “clinical trials update” as evidence-trend monitoring for formulary behavior, not as a driver of brand-level protection.

How does Precedex market share perform versus generic dexmedetomidine and competitors?

Core market dynamics

Hospital markets for sedation products are shaped by:

• Filing and contracting: when generics enter, hospitals often switch on acquisition cost.
• Supply continuity: stable availability supports formulary loyalty.
• Dosing convenience: concentration, labeling, and compatibility with infusion systems affect switching friction.
• Clinical preference: dexmedetomidine’s sedation profile can sustain use even under generic substitution.

Competitive set

Direct competitive substitution is mainly generic dexmedetomidine products. Indirect competition includes:

• propofol
• benzodiazepines (midazolam, lorazepam)
• other sedatives depending on institution protocols

Commercial takeaway: Branded Precedex competes most directly with therapeutic equivalents rather than a different mechanism.

What is the exclusivity timeline for Precedex and when does exclusivity end?

For a mature small molecule like dexmedetomidine, the exclusivity landscape is typically:

• drug substance patent expiry (core chemical)
• product/formulation and use patent expiry (concentration, composition, method)
• possible pediatric exclusivity or regulatory exclusivity depending on labeling history and applicable US triggers

Market consequence: Once the last relevant patent or exclusivity barrier is cleared, generic launch risk rises sharply and branded pricing pressure increases quickly.

How many patents cover Precedex in the Orange Book and what do they protect?

For FDA product-level exclusivity, the Orange Book is the operational register for:

• patents listed for approved products
• patent expiration dates used in Paragraph IV strategy
• method-of-use vs formulation vs composition-of-matter coverage

Actionable framework for investors and litigators

• Map patents by claim type:
  • formulation/composition protection
  • method-of-use protection (sedation in specific populations or settings)
  • device/administration adjunct claims (if listed)
• Identify expirations by jurisdiction and listed formulation strength
• Separate where generic entry is blocked from where it is only partially blocked (e.g., specific concentration or dosing)

What generic entry risks exist for Precedex and what triggers Paragraph IV challenges?

Paragraph IV structure for a mature small molecule

A generic entrant files an ANDA with a claim of non-infringement/invalidity against Orange Book-listed patents for the reference product. Generic entry is likely when:

• key patents expire
• remaining patents are weak or easily design-around
• a settlement supports “at-risk” or delayed launch windows

Commercial risk if multiple listings exist

Even if some patents expire, others can delay launch. Risk is highest when:

• multiple method-of-use patents remain
• formulation patents cover the marketed concentration and administration pathway
• litigation creates an automatic stay (in certain cases) or settlement delay

What patent litigation affects Precedex and how do settlement agreements change launch timing?

In small-molecule sedation categories, litigation and settlements often result in:

• entry at a defined “carve-out” date
• design-around products
• licensing arrangements that preserve delayed launch for a period

Business-use projection rule: The most reliable launch timing inputs are:

• last day of any relevant listed patent term
• settlement date commitments
• court decisions on enjoined claims or validity

What is the FDA regulatory status of Precedex today (pathway, supplements, labeling)?

Precedex is an approved drug with established manufacturing and labeling history. Regulatory status affects market through:

• labeling-driven hospital adoption
• supplement-driven manufacturing changes
• updates that support evidence-based protocol usage

For projection, the key question is whether:

• new labeling expands indication scope (supporting volume growth)
• new formulation changes enable improved contract positioning

How does Precedex compare with other ICU sedation drugs on clinical outcomes and cost?

Clinical differentiation that persists through generic substitution

Even when the active ingredient is generic, dexmedetomidine adoption persists when it supports:

• lower need for rescue sedatives in targeted protocols
• reduced delirium signal vs some comparators in specific settings
• ventilator management workflows

Cost positioning

Hospitals typically treat substitution as:

• direct acquisition cost
• total cost of care (length of stay, rescue medication usage)
• staff familiarity and order set standardization

Market outcome: Generic dexmedetomidine usually compresses brand pricing unless Precedex holds a contract advantage or supply reliability premium.

Market projection: What revenues and volume growth scenarios are most plausible for Precedex?

Projection logic for a mature branded small molecule

• When generics expand, brand revenue typically becomes a share and price story.
• Brand may maintain revenue if it:
  • retains formulary coverage via contracting
  • offers reliable supply
  • keeps clinicians aligned to dexmedetomidine protocols

Three scenario framework (launch and share)

1. Status quo scenario: limited switching due to contracts and institutional protocol preference.
2. Gradual switch scenario: generic penetration increases, with Precedex share declining but not collapsing.
3. Accelerated switch scenario: multiple generic launches coincide with policy changes and aggressive contracting, compressing price faster than volume declines.

Near-term driver: US generic entry timing depends on remaining Orange Book barriers and litigation outcomes.

What manufacturing and supply chain/IP barriers influence generic uptake for dexmedetomidine?

For sterile injectables:

• manufacturing capacity and batch release consistency matter more than patent breadth once cleared
• procurement fragmentation can delay switching even when generics are approved
• shortages can temporarily protect branded share

Net impact: Generic uptake can be slower than predicted by exclusivity end dates alone.

Key data tables used for decisioning

Precedex commercial use cases (volume drivers)

Setting	How dexmedetomidine is used	Switching propensity to generics
ICU	sedation infusions with targeting	medium to high
OR/MAC	procedural sedation with monitoring	medium

Launch projection inputs

Input	Market effect
Orange Book last patent expiration	defines earliest legal launch
Litigation stay/settlement	delays generic entry date
Generic launch breadth (multiple ANDAs)	accelerates price pressure
Contracting cycles (GPO/hospital systems)	controls speed of switching

Key Takeaways

• Precedex is a mature dexmedetomidine sedation product where clinical trial updates mainly influence protocol adoption, not brand exclusivity.
• Market performance is primarily driven by generic dexmedetomidine penetration, hospital contracting, and supply continuity.
• Launch and revenue projections hinge on Orange Book patent expirations, litigation posture, and settlement-defined entry windows.
• Competitive pressure is structural: once product-level barriers clear, branded pricing faces sustained compression.

FAQs

1. Do dexmedetomidine clinical trials change Precedex exclusivity or only support formulary adoption?
2. What Orange Book patent types (method of use vs formulation) most often delay generic dexmedetomidine?
3. How do settlement agreements typically shift FDA ANDA launch dates for sedation products?
4. Which ICU sedation endpoints (delirium, ventilation duration) most influence hospital formulary decisions?
5. What factors besides patent expiry slow generic uptake for sterile injectables like Precedex?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. ClinicalTrials.gov. Search results for dexmedetomidine studies (trial listings and status updates).
3. FDA Prescribing Information for Precedex (dexmedetomidine hydrochloride), current label.